联合系统治疗：现状与未来展望。
Concomitant Systemic Therapy: Current and Future Perspectives.
机构信息
Department of Internal Medicine, Division of Medical Oncology, Keck School of Medicine of USC, Los Angeles, California, USA.
Department of Radiation Oncology, Keck School of Medicine of USC, Los Angeles, California, USA.
出版信息
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):e257-e263. doi: 10.1016/j.clon.2021.03.021. Epub 2021 Apr 21.
PMID:33895060
Abstract
Chemotherapy in combination with radical cystectomy or radiotherapy has led to improved oncological outcomes in the definitive treatment of muscle-invasive bladder cancer (MIBC). Here we discuss the current role of chemotherapy and immunotherapy in the management of MIBC and discuss future directions of treatment.
摘要
化疗联合根治性膀胱切除术或放疗已改善肌层浸润性膀胱癌（MIBC）确定性治疗的肿瘤学结局。本文讨论了化疗和免疫治疗在 MIBC 治疗中的当前作用，并探讨了未来的治疗方向。
相似文献
1
Concomitant Systemic Therapy: Current and Future Perspectives.联合系统治疗：现状与未来展望。
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):e257-e263. doi: 10.1016/j.clon.2021.03.021. Epub 2021 Apr 21.
2
Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?肌肉浸润性膀胱癌的新辅助治疗和辅助治疗：我们目前的进展如何？
Arch Esp Urol. 2020 Dec;73(10):971-985.
3
Current Perioperative Therapy for Muscle Invasive Bladder Cancer.当前肌层浸润性膀胱癌的围手术期治疗。
Hematol Oncol Clin North Am. 2021 Jun;35(3):495-511. doi: 10.1016/j.hoc.2021.02.002. Epub 2021 Apr 16.
4
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌新辅助化疗和辅助化疗的系统评价。
Eur Urol. 2012 Sep;62(3):523-33. doi: 10.1016/j.eururo.2012.05.048. Epub 2012 Jun 1.
5
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.新辅助化疗对比单纯根治性膀胱切除术改善肌层浸润性膀胱癌患者总生存的荟萃分析。
BMC Urol. 2020 Oct 14;20(1):158. doi: 10.1186/s12894-020-00733-z.
6
Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.肌层浸润性膀胱癌围手术期治疗的现状与未来方向
Curr Oncol Rep. 2023 May;25(5):511-520. doi: 10.1007/s11912-023-01390-9. Epub 2023 Mar 10.
7
Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.浸润性膀胱癌的手术与化疗联合治疗：现状与未来方向
Expert Rev Anticancer Ther. 2006 Feb;6(2):281-91. doi: 10.1586/14737140.6.2.281.
8
Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions.肌层浸润性膀胱癌的新辅助治疗：当前临床现状、未来展望和未解决的问题。
Crit Rev Oncol Hematol. 2022 Oct;178:103795. doi: 10.1016/j.critrevonc.2022.103795. Epub 2022 Aug 19.
9
Neoadjuvant chemotherapy in patients with invasive bladder cancer.浸润性膀胱癌患者的新辅助化疗
Urol Clin North Am. 2005 May;32(2):231-7. doi: 10.1016/j.ucl.2005.03.001.
10
Trimodal therapy in muscle invasive bladder cancer management.肌层浸润性膀胱癌治疗中的三联疗法。
Minerva Urol Nefrol. 2020 Dec;72(6):650-662. doi: 10.23736/S0393-2249.20.04018-7.
引用本文的文献
1
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.肌层浸润性膀胱癌的围手术期全身治疗：当前的标准方法、生物标志物和新兴策略。
Investig Clin Urol. 2023 May;64(3):202-218. doi: 10.4111/icu.20230006.
2
Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations.肌层浸润性膀胱癌新辅助化疗后临床完全缓解的方法：可能性与局限性
Cancers (Basel). 2023 Feb 19;15(4):1323. doi: 10.3390/cancers15041323.
Zotero 插件